Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Company Overview - Chemomab Therapeutics Ltd. is a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need [3] - The company has developed nebokitug, a first-in-class dual activity monoclonal antibody that neutralizes the soluble protein CCL24, which plays a role in promoting fibrosis and inflammation [3] - Nebokitug has shown disease-modifying potential and a favorable safety profile in clinical and preclinical studies, with positive results reported from five clinical trials [3] Clinical Development - Chemomab has aligned with the FDA on the design of a Phase 3 registration trial for nebokitug in patients with primary sclerosing cholangitis (PSC) based on positive data from its Phase 2 SPRING trial [3] - Nebokitug has received Orphan Drug designations from the FDA and EMA for the treatment of PSC, as well as Fast Track designation from the FDA [3] - The nebokitug program for systemic sclerosis has also received Orphan Drug designations and has an open U.S. IND [3] Upcoming Events - Chemomab's CEO Dr. Adi Mor and senior management will present at the virtual Oppenheimer 36 Annual Healthcare Life Sciences Conference on February 26, 2026 [1] - The corporate presentation will be webcast live and available for 90 days on the Chemomab investor relations website [1]